A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

BACKGROUND: This phase I study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics and antitumor activity of ganetespib in patients with solid malignancies. METHODS: Patients were enrolled in cohorts of escalating ganetespib doses, given as 1 hour IV infusion, once weekly for 3 w...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Goldman, Jonathan W, Raju, Robert N, Gordon, Gregory A, El-Hariry, Iman, Teofilivici, Florentina, Vukovic, Vojo M, Bradley, Robert, Karol, Michael D, Chen, Yu, Guo, Wei, Inoue, Takayo, Rosen, Lee S
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BioMed Central 2013
विषय:
Research Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3626541/
https://ncbi.nlm.nih.gov/pubmed/23530663
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-152
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन